Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 3/20 | 0.53 |
| ▸ | MAPT | P10636 | 3/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | KDR | P35968 | 1/20 | 0.49 |
| ▸ | CCR2 | P41597 | 1/20 | 0.48 |
| ▸ | CCR5 | P51681 | 1/20 | 0.48 |
| ▸ | EGFR | P00533 | 9/20 | 0.48 |
| ▸ | BRAF | P15056 | 1/20 | 0.47 |
| ▸ | ABCG2 | Q9UNQ0 | 2/20 | 0.47 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.47 |
| ▸ | FBP1 | P09467 | 1/20 | 0.47 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3053997 | 0.87 | EGFR (0.51) | TP53MAPTSMN1; SMN2POLBCCR2 | |
| SCHEMBL13310235 | 0.83 | MAPT (0.46) | TP53MAPTSMN1; SMN2POLBKDR | |
| SCHEMBL3051395 | 0.80 | SMN1; SMN2 (0.55) | TP53MAPTSMN1; SMN2POLBCCR2 | |
| SCHEMBL3056423 | 0.80 | TP53 (0.63) | TP53MAPTSMN1; SMN2POLBCCR2 | |
| SCHEMBL22542653 | 0.80 | TP53 (0.64) | TP53MAPTSMN1; SMN2POLBCCR2 | |
| SCHEMBL30754751 | 0.80 | SMN1; SMN2 (0.55) | TP53MAPTSMN1; SMN2POLBCCR2 | |
| SCHEMBL20570805 | 0.80 | TP53 (0.53) | TP53MAPTSMN1; SMN2POLBCCR2 | |
| SCHEMBL18292306 | 0.79 | EGFR (0.40) | TP53MAPTSMN1; SMN2KDRCCR2 | |
| SCHEMBL3051333 | 0.78 | MAPT (0.54) | TP53MAPTSMN1; SMN2POLBCCR2 | |
| SCHEMBL20570334 | 0.76 | MAPT (0.85) | TP53MAPTSMN1; SMN2POLBCCR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120178754-A1 | Furazano '3, 4-B! Pyrazines and Their Use as Anti-Tumor Agents | COMPASS PHARMACEUTICALS LLC (US) | 2012-07-12 | — | — | US | claimed |
| US-20100222356-A1 | Furazano '3, 4-B! Pyrazines and Their Use as Anti-Tumor Agents | COMPASS PHARMACEUTICALS LLC (US) | 2010-09-02 | — | — | US | claimed |
| US-20090131445-A1 | Furazano '3, 4-B! Pyrazines and Their Use as Anti-Tumor Agents | COMPASS PHARMACEUTICALS LLC (US) | 2009-05-21 | — | — | US | claimed |
| EP-1799689-A1 | FURAZANO `3, 4-B ! PYRAZYNES AND THEIR USE AS ANTI-TUMOR AGENTS | Compass Pharmaceuticals LLC (US) | 2007-06-27 | — | — | EP | claimed |
| WO-2006044402-A1 | FURAZANO `3, 4-B ! PYRAZYNES AND THEIR USE AS ANTI-TUMOR AGENTS | COMPASS PHARMACEUTICALS LLC (US) | 2006-04-27 | — | — | WO | claimed |
| US-20120178754-A1 | Furazano '3, 4-B! Pyrazines and Their Use as Anti-Tumor Agents | COMPASS PHARMACEUTICALS LLC (US) | 2012-07-12 | — | — | US | disclosed |
| US-20100222356-A1 | Furazano '3, 4-B! Pyrazines and Their Use as Anti-Tumor Agents | COMPASS PHARMACEUTICALS LLC (US) | 2010-09-02 | — | — | US | disclosed |
| US-20090131445-A1 | Furazano '3, 4-B! Pyrazines and Their Use as Anti-Tumor Agents | COMPASS PHARMACEUTICALS LLC (US) | 2009-05-21 | — | — | US | disclosed |
| EP-1799689-A1 | FURAZANO `3, 4-B ! PYRAZYNES AND THEIR USE AS ANTI-TUMOR AGENTS | Compass Pharmaceuticals LLC (US) | 2007-06-27 | — | — | EP | disclosed |
| WO-2006044402-A1 | FURAZANO `3, 4-B ! PYRAZYNES AND THEIR USE AS ANTI-TUMOR AGENTS | COMPASS PHARMACEUTICALS LLC (US) | 2006-04-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100222356-A1 | Furazano '3, 4-B! Pyrazines and Their Use as Anti-Tumor Agents | CDC73, VHL, RB1 | TP53 4/4885MAPT 3908/4885SMN1; SMN2 243/4885 |
| US-20090131445-A1 | Furazano '3, 4-B! Pyrazines and Their Use as Anti-Tumor Agents | CDC73, RB1, CA5A | TP53 6/4885MAPT 4220/4885SMN1; SMN2 247/4885 |
| US-20120178754-A1 | Furazano '3, 4-B! Pyrazines and Their Use as Anti-Tumor Agents | CDC73, VHL, RB1 | TP53 4/4885MAPT 3908/4885SMN1; SMN2 243/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.